Conclusions
MitraClip therapy is a safe procedure in selected high-risk patients and can be accomplished with low morbidity and mortality.
MV repair is the preferred treatment for degenerative MV regurgitation. However, Mitraclip implantation should be considered for high-risk surgical patients.
For FMR, Mitraclip is a valuable clinical option in patients with adequate anatomy who are considered inoperable or with a high surgical risk, and should be considered as an important therapeutic modality in the multidisciplinary treatment of heart failure. We need to treat patients at an earlier stage to achieve better prognostic outcomes.